Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06837298 · ClinicalTrials.gov registry record · NA
The Effect of Vicia Faba Hydrolysate Supplementation on Muscle Strength Recovery
A NA study of Muscle Damage and Muscle, sponsored by PepsiCo Global R&D.
- Recruiting
- Registry status
- NA
- Development phase
- 76
- Enrollment target
- 1
- Study location
NCT06837298: Recruiting NA study of Muscle Damage and Muscle, sponsored by PepsiCo Global R&D.
NCT06837298 is a NA study of Muscle Damage and Muscle that is actively recruiting participants, run by PepsiCo Global R&D. The registered enrollment target is 76 participants, above the 32-participant average among 6 other Muscle Damage trials with a reported enrollment target (138% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06837298, a NA study of Muscle Damage and Muscle, is actively recruiting participants, sponsored by PepsiCo Global R&D.
- RECRUITING
- Registry status
- NA
- Development phase
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
To investigate the effect of Vicia faba protein concentrate, a protein derived from Fava bean extract, on delayed onset muscle soreness (DOMS). Participants receive either 2.4g/day of PeptiStrong® supplement capsules or placebo capsules for 14 days until a strenuous exercise session. For the last 3 days, 2/3 of them stay on the same treatment and 1/3 of them switch from placebo to PeptiStrong®.
Primary Outcome
Assessed at an angular velocity of 60°/s through the range of 0-100° knee flexion using an isokinetic dynamometer (Biodex)
Conditions Studied
Interventions
- OTHER Placebo control capsules
- OTHER PeptiStrong® supplement capsules with same appearance as placebo capsules
- OTHER PeptiStrong® supplement capsules following muscle damaging exercise on Day 14
Study Locations (1)
Florida
- Gatorade Sports Science Institute at IMG Academy - Bradenton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2025-02-07 |
| Est. Completion | 2025-09-30 |
| Phase | NA |
What NCT06837298 shows while recruiting
NCT06837298 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, above the 32-participant average among 6 other Muscle Damage trials with a reported enrollment target (138% higher).
The record links to 2 conditions, with Muscle Damage appearing as the primary indexed condition, and to 3 interventions - of which Placebo control capsules is the first listed.
NCT06837298 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06837298 about?
NCT06837298 is a clinical study titled "The Effect of Vicia Faba Hydrolysate Supplementation on Muscle Strength Recovery". To investigate the effect of Vicia faba protein concentrate, a protein derived from Fava bean extract, on delayed onset muscle soreness (DOMS). Participants receive either 2.4g/day of PeptiStrong® supplement capsules or placebo capsules for 14 days until a strenuous exercise session. For the last 3 ...
What is the current status of trial NCT06837298?
This trial is currently recruiting. It is a NA study. The enrollment target is 76 participants. The study started on 2025-02-07. Estimated completion is 2025-09-30.
What conditions does trial NCT06837298 study?
This clinical trial studies the following conditions: Muscle Damage, Muscle.
What interventions are being tested in trial NCT06837298?
The interventions under investigation include: Placebo control capsules (OTHER), PeptiStrong® supplement capsules with same appearance as placebo capsules (OTHER), PeptiStrong® supplement capsules following muscle damaging exercise on Day 14 (OTHER).
Who is sponsoring clinical trial NCT06837298?
This trial is sponsored by PepsiCo Global R&D, which has 47 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06837298 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscle Damage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing Two Eccentric Protocols on Muscle Damage
RECRUITING · NA
-
Solarplast (R) Supplementation Effects Following High-intensity Resistance Exercise
RECRUITING · NA
-
HIFEM and Radiofrequency for Muscular System Function Improvement
ACTIVE NOT RECRUITING · NA
-
Protein and Recovery From Exercise-induced Muscle Damage
COMPLETED · NA
-
Comparison of Pre-exercise Beta-hydroxy-beta-methylbutyrate Free Acid (HMB-FA) and Cold Water Therapy for the Attenuation of Muscle Damage and Soreness
COMPLETED · NA
-
The Long-term Effects of Oceanix™ on Resistance Training Adaptations
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI